Lebrikizumab-Treated Patients With Atopic Dermatitis Had No Increase in Treatment-Emergent Adverse Events of Facial, Head, and Neck Erythema Compared to Placebo. J of Skin [Internet]. 2023 Nov. 13 [cited 2025 Oct. 24];7(6):s272. Available from: https://skin.dermsquared.com/skin/article/view/2383